Abstracts tagged "immunology"

Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: LB18 • ACR Convergence 2025
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Rita Pozovskiy¹, Yemil Atisha-Fregoso² and Betty Diamond³, ¹Zucker School of Medicine, New York, New York, ²Feinstein Institutes for Medical Research, New York, New York, ³The Feinstein Institutes for Medical Research, Manhasset, New York
Background/Purpose: In systemic lupus erythematosus (SLE), IgG antibodies that target nuclear antigens (ANA) are pathogenic and part of the diagnostic criteria for SLE. Healthy individuals…
Abstract Number: 0054 • ACR Convergence 2025
Microbial Cues Promote Arthritis and Alter T Cell Selection in SKG Mice
Astha Patel¹, Steven yu¹, Yuka Nakao¹, Mohana Mukherjee¹, Diego Orellana², Jose Scher³, Peter Turnbaugh¹, Renuka Nayak⁴ and Judith Ashouri¹, ¹University of California, San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³New York University School of Medicine, New York, NY, ⁴University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Dysbiosis of the gut microbiota has been linked to rheumatoid arthritis (RA), but it remains unclear whether these microbial alterations are causal or secondary…
Abstract Number: 0857 • ACR Convergence 2025
CD14-dependent MAP kinase signaling is required for pathogenic neutrophil extracellular trap formation in APS
Thalia Newman¹, NaveenKumar Somanathapura¹, Chao Liu², Srilakshmi Yalavarthi¹, Pooja Kapoor¹, Ajay Tambralli¹, Jacqueline Madison¹, Yu (Ray) Zuo¹ and Jason S. Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Superior Charter Twp, MI
Background/Purpose: Antibodies targeting beta-2-glycoprotein I (anti-β2GPI) promote inflammation and thrombosis in antiphospholipid syndrome (APS). It has been shown that anti-β2GPI activate neutrophils through Toll-like receptor…
Abstract Number: 0917 • ACR Convergence 2025
Synovial Tissue Neutrophils are Associated with Disease Activity and Early Remission in Rheumatoid Arthritis
Annabelle Small¹, Vincent Wong², Christopher Altmann¹, Helen Weedon³, Malcolm Smith⁴, Susanna Proudman⁵ and Mihir Wechalekar⁶, ¹Flinders University, Bedford Park, South Australia, Australia, ²College of Medicine and Public Health, Bedford Park, South Australia, Australia, ³Flinders University of South Australia, Bedford Park, South Australia, Australia, ⁴Flinders University, Adelaide, South Australia, Australia, ⁵Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁶Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Neutrophils drive local pathology of rheumatoid arthritis (RA) in the synovial tissue (ST) through local production inflammatory mediators, cytokines, and extracellular traps. However, despite…
Abstract Number: 1103 • ACR Convergence 2025
Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Kayla Chubbs¹, Carrie Ye², Shahin Jamal³, Marie Hudson⁴, Janet Pope⁵, Tom Appleton⁶, Sabrina Hoa⁷, Alexandra Saltman⁸, Megan Himmel⁸, Nancy Maltez⁹, Faiza Khokhar¹⁰, Alexandra Ladouceur¹¹, Ines Colmegna¹², May Choi¹³, Manar Elsayed² and Janet Roberts¹, ¹Dalhousie University, Halifax, NS, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶Western University, London, ON, Canada, ⁷University of Montreal, Brossard, QC, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ¹⁰Hamilton Ontario, Hamilton, ON, Canada, ¹¹University of Montreal, Montreal, QC, Canada, ¹²The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹³University of Calgary, Calgary, AB, Canada
Background/Purpose: The use of immune checkpoint inhibitors (ICI) continues to increase with an expanding number of indications across varying cancer types and stages. ICIs can…
Abstract Number: 1646 • ACR Convergence 2025
The Obesity Paradox in Rheumatoid Arthritis: A Propensity-Matched Analysis of Mortality and Cardiovascular Outcomes
Queeneth Edwards¹, Chukwuemelie Okeke², Justin Riley³, Ufuoma Mamoh⁴ and Chekwube Obianyo⁵, ¹Georgia Southern University, Statesboro, GA, ²Maimonides Medical Center, Brooklyn, NY, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ⁵Georgia Southern University, statesboro
Background/Purpose: Obesity is traditionally associated with increased morbidity and mortality in the general population. However, in chronic inflammatory conditions like rheumatoid arthritis (RA), an "obesity…
Abstract Number: 1813 • ACR Convergence 2025
Frequency of Tissue-Specific Activated CD8+ T Cells is Correlated To Disease Severity in Juvenile Idiopathic Arthritis
Abigail Thielbar¹, Tracy Ting², Lexi Auld³, Kelly Rogers⁴, Megan Quinlan-Waters⁵, Sheila Angeles-Han⁴, Ekemini Ogbu², Daniel Lovell², Jennifer Huggins⁶, Grant Schulert², Yuriy Baglaenko⁴ and Patricia Vega-Fernandez², ¹Cincinnati Children's Hospital, Cincinnati, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, CCHMC, ⁶Cincinnati Children's Medical Center, Cincinnati, OH
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is characterized by joint pain and inflammation. Persistent oligoarticular JIA(oligoJIA) is defined by the involvement of up to 4 joints…
Abstract Number: 2399 • ACR Convergence 2025
Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine
Gregg Silverman¹, Abhimanyu Amarnani², Zakia Azad² and Brad Rovin³, ¹NYU Grossman School of Medicine, New York, NY, ²New York University Grossman School of Medicine, New York, NY, ³The Ohio State University, Columbus, OH
Background/Purpose: During disease, ~50% of SLE patients develop lupus nephritis (LN), one of the most serious complication. Despite the best therapy, within 15 years, ~20%…
Abstract Number: 0055 • ACR Convergence 2025
TCR Signaling Thresholds Govern Anergy and Tolerance in ZAP70 Hypomorphic Models of Autoimmune Arthritis
Yuka Nakao, Astha Patel, Letitia Yang, Steven yu, Arthur Weiss and Judith Ashouri, University of California, San Francisco, San Francisco, CA
Background/Purpose: T cell receptor (TCR) signaling strength is a key determinant of immune tolerance and autoimmunity, yet the threshold needed to prevent pathogenic self-reactivity remains…
Abstract Number: 0864 • ACR Convergence 2025
Immunophenotyping Reveals Upregulated IL-9R on Circulating T and B Cells in Dermatomyositis
Danica Lee¹, Daniel Reay², Timothy Oriss², Didem Saygin³, Dana Ascherman⁴ and Daniella Schwartz⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, ³Rush University Medical Center, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM), or myositis, comprise a group of autoimmune diseases with significant morbidity, yet the pathogenesis of myositis remains incompletely understood. In…
Abstract Number: 0923 • ACR Convergence 2025
Influenza Virus Infection Alters the MHC Class II Self-Immunopeptidome to Present Lupus-Associated Autoantigens
Julia Rood¹, Stephanie Suh Kyung Yoon², Mary Heard¹, Michael Hogan², Nicola Ternette³, Edward Behrens⁴ and Laurence Eisenlohr¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Dundee, Dundee, Scotland, United Kingdom, ⁴CHOP, West Chester, PA
Background/Purpose: Viral infections and major histocompatibility complex class II (MHC II) are both implicated in the genesis of systemic lupus erythematosus (SLE), but a mechanistic…
Abstract Number: 1109 • ACR Convergence 2025
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Laurianne Simard¹, Nathalie Amiable², Ines Colmegna³, Anne-Sophie Julien⁴, Sonia Léger-Thériault⁵, Alexandra Godbout⁴, Lison Fournier⁶, Giuliana Alfonso⁵, Josiane Bourre-Tessier⁷, Marie Hudson⁸, Nicolas Richard⁹, Jean-Paul Makhzoum¹⁰, Arielle Mendel¹¹, Sasha Bernatsky¹², Marc Dionne⁶, Michael Libman⁵, Gaston De Serres⁶ and Paul Fortin¹³, ¹Universite Laval, Quebec, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Centre de recherche du CHU de Québec – Université Laval, Quebec, QC, Canada, ⁵MUHC, Montreal, Canada, ⁶Centre de recherche du CHU de Québec – Université Laval, Quebec, Canada, ⁷Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁸McGill University, Montréal, QC, Canada, ⁹Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁰Universite de Montreal, Montreal, Canada, ¹¹McGill University Health Centre, Montréal, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…
Abstract Number: 1653 • ACR Convergence 2025
Gut-joint lymphocyte trafficking functions to regulate systemic immunity
Sarah Danielson¹, Sucai Liu² and Kristine Kuhn³, ¹University of Colorado Anschutz Medical Campus, Aurora, ²University of Colorado School of Medicine, Aurora, CO, ³²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO
Background/Purpose: The gut-joint and mucosal origins hypotheses postulate that immune alterations in mucosal sites may precede and impact the development of rheumatoid arthritis and spondyloarthritis.…
Abstract Number: 1829 • ACR Convergence 2025
Multiomic Investigation of Juvenile Idiopathic Arthritis Synovium Reveals Immune Cell Heterogeneity
Abigail Thielbar¹, Tracy Ting², Lexi Auld³, Kelly Rogers⁴, Megan Quinlan-Waters⁵, Sheila Angeles-Han⁴, Ekemini Ogbu², Daniel Lovell², Jennifer Huggins⁶, Grant Schulert², Patricia Vega-Fernandez² and Yuriy Baglaenko⁴, ¹Cincinnati Children's Hospital, Cincinnati, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, CCHMC, ⁶Cincinnati Children's Medical Center, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood, affecting 1:1,000 children worldwide. The hallmark of JIA is immune-mediated…

1
2
3
…
33
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].